Literature DB >> 24471972

Barriers to the delivery of optimal antidiabetic therapy in the Middle East and Africa.

M A Almaatouq1, M Al-Arouj, A Amod, S H Assaad-Khalil, S N Assaad, S T Azar, K Esmat, A A K Hassoun, N Jarrah, S Zatari.   

Abstract

BACKGROUND: The prevalence of type 2 diabetes is increasing worldwide, but developing nations will bear a disproportionate share of this burden. Countries in the Middle East and Africa are in a state of transition, where marked disparities of income and access to education and healthcare exist, and where the relatively young populations are being exposed increasingly to processes of urbanisation and adverse changes in diet that are fuelling the diabetes epidemic. Optimising diabetes care in these nations is crucial, to minimise the future burden of complications of diabetes.
METHODS: We have reviewed the barriers to effective diabetes care with special relevance to countries in this region.
RESULTS: The effects of antidiabetic treatments themselves are unlikely to differ importantly in the region compared with elsewhere, but economic inequalities within countries restrict access to newer treatments, in particular. Values relating to family life and religion are important modifiers of the physician-patient interaction. Also, a lack of understanding of diabetes and its treatments by both physicians and patients requires more and better diabetes education, delivered by suitably qualified health educators. Finally, sub-optimal processes for delivery of care have contributed to a lack of proper provision of testing and follow-up of patients in many countries.
CONCLUSION: Important barriers to the delivery of optimal diabetes care exist in the Middle East and Africa.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24471972     DOI: 10.1111/ijcp.12342

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

Review 1.  Potential use of NOACs in developing countries: pros and cons.

Authors:  Durga Bista; Leanne Chalmers; Luke Bereznicki; Gregory Peterson
Journal:  Eur J Clin Pharmacol       Date:  2014-05-11       Impact factor: 2.953

2.  An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin.

Authors:  Abdelmjid Chraibi; Shoorook Al-Herz; Bich Dao Nguyen; Djoko W Soeatmadji; Anil Shinde; Balasubramanian Lakshmivenkataraman; Samir H Assaad-Khalil
Journal:  Diabetes Ther       Date:  2017-05-18       Impact factor: 2.945

3.  EADSG Guidelines: Insulin Therapy in Diabetes.

Authors:  Bahendeka Silver; Kaushik Ramaiya; Swai Babu Andrew; Otieno Fredrick; Sarita Bajaj; Sanjay Kalra; Bavuma M Charlotte; Karigire Claudine; Anthony Makhoba
Journal:  Diabetes Ther       Date:  2018-03-05       Impact factor: 2.945

Review 4.  Adherence to Low-Carbohydrate Diets in Patients with Diabetes: A Narrative Review.

Authors:  Nitya Kalyani Kumar; Jennifer D Merrill; Scott Carlson; Jashalynn German; William S Yancy
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-18       Impact factor: 3.168

Review 5.  Models of care for non-communicable diseases for displaced populations in Iraq: a scoping review.

Authors:  Benjamin Schmid; Éimhín Ansbro; Emmanuel Raju; Ruth Willis; Nazar Shabila; Pablo Perel
Journal:  Confl Health       Date:  2022-07-15       Impact factor: 4.554

Review 6.  Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review.

Authors:  Carla Castillo-Laborde; Macarena Hirmas-Adauy; Isabel Matute; Anita Jasmen; Oscar Urrejola; Xaviera Molina; Camila Awad; Catalina Frey-Moreno; Sofia Pumarino-Lira; Fernando Descalzi-Rojas; Tomás José Ruiz; Barbara Plass
Journal:  Public Health Rev       Date:  2022-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.